Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

The TWILIGHT of aspirin post-PCI for ACS?

Key clinical point: Patients do better post-PCI for non-ST-elevation ACS with ticagrelor monotherapy after 3 months of DAPT.

Major finding: Ticagrelor monotherapy after 3 months of DAPT reduced the risk of clinically significant bleeding by 53%, compared with continued DAPT in high-risk patients after PCI for non-ST-elevation ACS.

Study details: This prespecified subgroup analysis of the TWILIGHT study included 4,614 patients who underwent PCI for non-ST-elevation ACS and 3 months of DAPT with ticagrelor and aspirin followed by double-blind randomization to a further year on the same regimen or to ticagrelor plus placebo.

Disclosures: The presenter reported receiving honoraria from AstraZeneca, the study sponsor.


Baber U. AHA late breaker.